How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Health Technology Assessment (HTA) essentially began in the 1970s in Europe, with a more formalized implementation by the mid-to-late 80s in countries such as Sweden, the Netherlands, Australia and Canada. Shortly thereafter, other countries started establishing agencies, notably France, Spain and eventually the UK with the creation of NICE in 1999.

Today, virtually every country has a national program on HTA.

This 1992 article via @CMAJ presents one the first framework HTA agencies drew upon to interpret economic evaluations and to identify additional information that will be pertinent in making sound reimbursement decisions. Its presents actual 'grades' of recommendation on adoption and utilization, based on the QALY.

This guideline is still in use today.

Fundamental reading from researchers who pioneered how to classify therapies on the basis of the magnitude of their incremental net benefits.

Comments